Founded in November 2010, P&K Skin Research Center was established to provide scientific and systematic technical support and information according to various customers’ demands about clinical tests for developing new ingredients as well as functional cosmetics and quasi-drugs. P&K Skin Research Center started through a strategic alliance with Daebong LS Ltd, which is the only company manufacturing and selling pharmaceutical and cosmetic and healthy functional food ingredients, and Chung-ang University Research Center for Medical Scieces, which was the first research center to own a general hospital in Korea.
P&K Skin Research Center is equipped with facilities that meet not only the KFDA and EU guidelines but also US standards. Through analyzing all functional stroma and protocol from physical through to chemical inspection techniques for pharmaceutical ingredients, and through 30 years’ history of Daebong LS, we clinically test efficacy of general cosmetic and functional ingredients and cosmetics in accordance with KFDA, EU and US guidelines. Through these scientific evaluations, we are trying to provide scientific technical support and information for consumer satisfaction about products directly applied to the skin.
We do our utmost to ensure scientific validity, objectivity and also transparency for efficacy and functionality evaluation with Daebong LS, which has abundant clinical experiences at manufacturing and analysis, especially for pharmaceutical and cosmetic ingredients, and our experts include a dermatologist of a university hospital who has various clinical test experiences.
Contact details:
City B/D 2F, 118-2 Heukseok-dong, Dongjak-gu, Seoul 156-860 Korea
+82 2 6295 1501~3
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
See our Cookie Privacy Policy Here
